Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Stemline Therapeutics, Inc.
Francois-Clement Bidard; Virginia G Kaklamani; Patrick Neven; Guillermo Streich; Alberto J Montero; Frédéric Forget; Marie-Ange Mouret-Reynier; Joo Hyuk Sohn; Donatienne Taylor; Kathleen K Harnden; Hung Khong; Judit Kocsis; Florence Dalenc; Patrick M Dillon; Sunil Babu; Simon Waters; Ines Deleu; José A García Sáenz; Emilio Bria; Marina Cazzaniga; Janice Lu; Philippe Aftimos; Javier Cortés; Shubin Liu; Giulia Tonini; Dirk Laurent; Nassir Habboubi; Maureen G Conlan; Aditya Bardia